Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Recurrent Malignant Glioma

Inclusion Criteria: * Patients must be 18 to 70 years old, signed ICF; * At least 4 weeks after previous chemotherapy (6 weeks since nitrosoureas); * KPS ≥ 60; * Unilateral, Supratentorial, solitary lesion and not crossing the midline(exclude patients with little tumors near the resectable tumor even if investigators think they are single lesions) * No obvious important organ dysfunction: Blood routine: White blood cell (WBC) ≥ 4.0×109/L, Absolute neutrophil count (ANC)≥ 1.5×109/L, Platelets≥ 100×109/L, Hemoglobin≥ 90 g/L; Hepatic function:Serum total bilirubin ≤1.5 times upper limit of laboratory normal; Aspartate aminotransferase (AST) and/or Alanine aminotransferase (ALT)\<2.5 times upper limit of laboratory normal; Renal function:Serum creatinine ≤1.5 times upper limit of laboratory normal; * Not Pregnant or lactating for women of childbearing potential. Exclusion Criteria: * Tumor located at ventricular system, Open ventricle tumor cavity postoperatively; * Concomitant with other life-threatening diseases and with life expectancy \<3 months; * Allergic to nitrosourea drugs; * With history of intracranial radiotherapy or implant chemotherapy; * With serious cardiac, pulmonary, hepatic and renal dysfunction, poor glycemic control; * Investigators thought unsuitable for enrollment.